Nos­trum agrees to $50M set­tle­ment with DOJ over al­le­ga­tions of un­der­pay­ing Med­ic­aid

Mis­souri-based phar­ma Nos­trum Lab­o­ra­to­ries and its CEO have agreed to pay a min­i­mum $3.8 mil­lion and up to $50 mil­lion to set­tle ac­cu­sa­tions from the US De­part­ment of Jus­tice that the com­pa­ny vi­o­lat­ed the False Claims Act.

Ac­cord­ing to the DOJ, Nos­trum and its CEO were “know­ing­ly un­der­pay­ing Med­ic­aid re­bates due for Nos­trum’s drug Ni­tro­fu­ran­toin Oral Sus­pen­sion” af­ter hik­ing up the price of the an­tibi­ot­ic. The set­tle­ment could go up to $50 mil­lion if cer­tain fi­nan­cial con­tin­gen­cies are met, though the de­part­ment did not spec­i­fy the con­tin­gen­cies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.